Skip to main content
Suresh Ramalingam, MD, Oncology, Atlanta, GA

Suresh Sakkarai Ramalingam MD FACP, FASCO

Oncology•Atlanta, GA

Hematologic Oncology, Thoracic Cancer

Executive Director, Winship Cancer Institute of Emory University

Join to view full profile

  • 1365 Clifton Rd NE# WinshipAtlanta, GA 30322

  • Phone+1 404-778-5961

  • Fax+1 404-778-5520

Dr. Ramalingam is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Ramalingam's full profileAlready have an account?

Summary

  • Dr. Suresh Ramalingam is an oncologist based in Atlanta, GA, specializing in hematologic oncology and thoracic cancer. He completed his residency in internal medicine at Wayne State University School of Medicine and his fellowship in hematology and medical oncology at UPMC Medical Education. His clinical expertise includes pancreatic cancer, mesothelioma, lung cancer, thymoma, and hereditary breast/ovarian cancer. Dr. Ramalingam has authored several publications on topics such as treatment strategies for EGFR-mutant non-small-cell lung cancer and the therapeutic efficacy of osimertinib. He is involved in multiple clinical trials, serving as a principal investigator on studies involving low-dose interleukin-2 and pembrolizumab for stage IV non-small cell lung cancer, among others.

Education & Training

  • UPMC Medical Education
    UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2000 - 2003
  • Wayne State University School of Medicine
    Wayne State University School of MedicineResidency, Internal Medicine, 1993 - 1996
  • Kilpauk Medical College
    Kilpauk Medical CollegeClass of 1992

Certifications & Licensure

  • GA State Medical License
    GA State Medical License 2007 - 2027
  • PA State Medical License
    PA State Medical License 2000 - 2008
  • MI State Medical License
    MI State Medical License 1995 - 2002
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology
  • Internal Medicine
    National Board of Physicians and Surgeons Internal Medicine
  • Medical Oncology
    National Board of Physicians and Surgeons Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification FirstNet (Clinical), Cerner Corporation, 2017
  • CMS Meaningful Use Stage 1 Certification P2 Sentinel, Cerner Corporation, 2017
  • CMS Meaningful Use Stage 1 Certification HealtheLife and PowerChart, Cerner Corporation, 2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors  
    David S Hong, Marwan G Fakih, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Adrian Sacher, Crystal S Denlinger, John C Krauss, Andrew L Coveler, Suresh S Rama..., The New England Journal of Medicine
  • Concurrent Chemoradiotherapy with Weekly Versus Triweekly Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Comparative Analysis  
    Rathi Pillai, Fadlo R Khuri, Nabil F Saba, Conor Steuer, Suchita Pakkala, Kristin Higgins, Jonathan J Beitler, Suresh S Ramalingam, Brandon Twardy, Kelly Schrapp, Taof..., Head & Neck
  • Targeted Sequencing and Intracranial Outcomes of Patients with Lung Adenocarcinoma Brain Metastases Treated with Radiotherapy  
    Gabriel L Sica, Matthew J Ferris, Walter J Curran, Shannon Kahn, Suresh S Ramalingam, Pretesh R Patel, Rathi N Pillai, Robert H Press, Jim Zhong, Conor E Steuer, Taofe..., Cancer

Lectures

  • ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC. 
    2019 ASCO Annual Meeting - 6/1/2019

Other

Authored Content

  • How Immunotherapy Is Dramatically Changing Treatment for Non-Small and Small Cell Lung CancerOctober 2018

Press Mentions

  • Improved Outcomes Reported with Second-Line Regimen of Ivonescimab Plus Chemotherapy in NSCLC
    Improved Outcomes Reported with Second-Line Regimen of Ivonescimab Plus Chemotherapy in NSCLCOctober 8th, 2025
  • Editor's Corner—for the First PD-1xVEGf's Sake, Summit Must Submit to Big Pharma, Stat
    Editor's Corner—for the First PD-1xVEGf's Sake, Summit Must Submit to Big Pharma, StatSeptember 10th, 2025
  • Ivonescimab Delays Lung Cancer Progression in EGFR-Mutated Disease
    Ivonescimab Delays Lung Cancer Progression in EGFR-Mutated DiseaseSeptember 9th, 2025

Grant Support

  • Emory University Lung Cancer SPOREEMORY UNIVERSITY2026–2031
  • Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)EMORY UNIVERSITY2022–2028
  • Winship Cancer Institute Cancer Center Support GrantEMORY UNIVERSITY2009–2028
  • Administrative Supplement: Interim Funding for Emory Lung Cancer SPOREEMORY UNIVERSITY2019–2025
  • Administrative Supplement: Interim Funding for Emory Lung Cancer SPOREEMORY UNIVERSITY2019–2025

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Suresh Ramalingam, Dr. Suresh Ramalingam, MD, Dr. S Ramalingam, Dr. Suresh Sakkarai Ramalingam